
礼来公司周一表示,其肥胖症药片Foundayo在一项晚期临床试验中,显著降低了肥胖患者阻塞性睡眠呼吸暂停(最常见的睡眠相关呼吸障碍)的严重程度。
Eli Lilly on Monday said its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea, the most common sleep-related breathing disorder, in patients with obesity, in a late-stage trial.
该药企计划于年底前向美国申请批准,将这种每日一片的药物用于治疗患有肥胖或超重的成年人的中重度阻塞性睡眠呼吸暂停(OSA)。这一结果使该药片——于4月在美国推出——成为多款显示出治疗该病症前景的GLP-1疗法之一。
The drugmaker plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea, or OSA, in adults with obesity or who are overweight. The results make the pill — which rolled out in the U.S. in April — one of several GLP-1 treatments to show promise in treating the condition.
OSA是指因气道变窄或阻塞导致睡眠中呼吸中断,这会引起血氧下降和血压升高,并与高血压、心力衰竭和中风等严重并发症相关。根据国家老龄化委员会的数据,该病症在全球影响近10亿成年人,其中包括美国8000万20岁及以上人群。礼来在声明中表示,大多数患者从未被确诊。
OSA refers to interrupted breathing during sleep due to narrowed or blocked airways, which can cause drops in oxygen and increases in blood pressure that are associated with serious complications, such as hypertension, heart failure and stroke. The condition affects nearly 1 billion adults globally, including 80 million people ages 20 and over in the U.S., according to the National Council on Aging. Most have never been diagnosed, Lilly said in a release.
礼来的畅销减重注射剂Zepbound于2024年12月成为首个获美国批准用于治疗OSA的药物。除该药物外,患者的治疗选择有限,许多人只能使用笨重的正压通气(PAP)机器来维持正常呼吸。
Lilly's blockbuster weight loss injection Zepbound became the first medication to win U.S. approval for OSA in December 2024. Patients have limited treatment options outside of that drug and many use cumbersome machines that provide positive airway pressure, or PAP, to allow for normal breathing.
礼来心脏代谢健康部产品开发高级副总裁Thomas Seck博士在声明中表示:“Foundayo已经在改变肥胖患者的生活,我们计划于年底前向FDA提交这些结果,这将使我们有机会帮助OSA患者。”
"Foundayo is already making a difference for people living with obesity, and with plans to submit these results to the FDA by the end of the year, we could have the opportunity to help people living with OSA," Dr. Thomas Seck, senior vice president of product development of Lilly Cardiometabolic Health, said in a release.
该试验在两项独立研究中测试了Foundayo。第一项研究纳入了363名无法或不愿使用PAP疗法的患者。第二项研究纳入了349名在筛选时已接受PAP疗法至少三个月并在试验期间继续该治疗的患者。
The trial tested Foundayo in two independent studies, the first of which included 363 patients who were unable or unwilling to use PAP therapy. The second study included 349 people who were on PAP therapy for at least three months at the time of screening and continued that treatment during the trial.
两项研究中服用 Foundayo 的患者均从低剂量开始,并在四周的间隔内逐步增加剂量,直至达到不同的最大剂量。
Patients in both studies who took Foundayo started at a low dose and increased it gradually at four-week intervals to different maximum dosages.
研究人员专门考察了该药片对所谓呼吸暂停-低通气指数(AHI)的降低幅度,该指数记录每小时一个人呼吸出现受限或气道完全阻塞的次数。该指数用于评估阻塞性睡眠呼吸暂停的严重程度以及治疗该病症的疗效。
Researchers specifically examined how much the pill reduced the so-called apnea-hypopnea index, or AHI, which records the number of times per hour a person's breathing shows a restricted or completely blocked airway. The index is used to evaluate the severity of obstructive sleep apnea and the effectiveness of treatments for the condition.
根据结果,未使用 PAP(正压通气)治疗的服用 Foundayo 患者,在 52 周时每小时平均减少 21.1 次 AHI 事件,而安慰剂组平均减少 4.8 次。
People who took Foundayo and were not using PAP therapy had an average of 21.1 fewer AHI events per hour at 52 weeks, compared with an average reduction of 4.8 per hour for the placebo, according to the results.
Foundayo 在该组别中也达到了试验的第二个目标,总体 AHI 降低 43.8%,而安慰剂组降低 6.3%。礼来公司表示,Foundayo 组 31.5% 的参与者符合缓解或改善为轻度 OSA 的标准。
Foundayo also met the trial's second goal in that group, leading to an overall AHI reduction of 43.8% compared with a decrease of 6.3% for the placebo. Lilly said 31.5% of the participants in the Foundayo group met the criteria for remission or improvement to mild OSA.
同时,同时接受 Foundayo 和 PAP 治疗的患者,在 52 周时每小时平均减少 18.3 次 AHI 事件,而安慰剂组平均减少 5.5 次。
Meanwhile, patients who were on both Foundayo and PAP therapy had an average of 18.3 fewer AHI events per hour at 52 weeks, compared with an average reduction of 5.5 per hour for the placebo.
在该组别中,Foundayo 导致总体 AHI 降低约 27.5%,而安慰剂组降低 3%。公司表示,同时接受 Foundayo 和 PAP 治疗的参与者中,有 19.6% 也符合缓解或轻度 OSA 的标准。
Foundayo led to an overall AHI reduction of around 27.5% in that group, compared with a decrease of 3% for the placebo. The company said 19.6% of the participants on Foundayo and PAP therapy also met the criteria for remission or mild OSA.
Foundayo 还降低了所谓的睡眠呼吸暂停特异性低氧负荷——即衡量睡眠期间血氧水平下降的深度和持续时间。该指标在未使用 PAP 治疗的人群中下降 55.9%,在使用 PAP 治疗的人群中下降 45.8%。
Foundayo also reduced what's known as the sleep apnea-specific hypoxic burden — a measure of how deeply and for how long oxygen levels fall during sleep. That metric fell by 55.9% in people not using PAP therapy and 45.8% in those using it.
礼来公司表示,该药片在 52 周时还帮助各组患者体重减轻约 11%,并有助于降低炎症标志物。
Lilly said the pill also helped patients lose roughly 11% of their weight across groups at 52 weeks and helped to lower a marker of inflammation.
公司表示,Foundayo 的安全性数据及患者耐受性总体与该药片此前的试验结果一致。
The company said the safety data and how well patients tolerated Foundayo were generally consistent with previous trials on the pill.
在未使用PAP疗法的Foundayo受试者中,约12%因副作用退出试验,而安慰剂组为3.8%。同时,同时服用礼来药丸和PAP的受试者中,有6.8%因副作用停药,安慰剂组仅为0.6%。
Around 12% of people on Foundayo who were not using PAP therapy discontinued due to side effects, compared to 3.8% with the placebo. Meanwhile, 6.8% of those on both Lilly's pill and PAP discontinued the drug due to side effects, compared with 0.6% in the placebo group.
最常见的副作用为胃肠道反应,包括恶心、腹泻、便秘和呕吐,总体程度为轻度至中度。这与其他GLP-1类药物一致。
The most common side effects were gastrointestinal, including nausea, diarrhea, constipation and vomiting, and were generally mild to moderate in severity. That's consistent with other GLP-1 medications.